Herantis Announces Election of Hilde Furberg to the Board of Directors

Herantis Pharma Plc

Company release

15 April 2021 at 4:50 PM EET

Herantis Pharma Plc (“Herantis or the Company”) focuses on disease modifying therapies for debilitating neurodegenerative diseases, today announced the election of Hilde Furberg to the Herantis Board of Directors, effective 15 April 2021.

"We are pleased to welcome Hilde Furberg to the Herantis Board," said Timo Veromaa, Chairman of Herantis. "Hilde's deep experience in private and public Pharma/Biotech global businesses with strong global sales, marketing, strategy and management oversight will be invaluable to Herantis as we grow our business and pursue our mission to serve patients."

Mrs. Furberg is a former European Head of Rare Disease Europe/General Manager and Senior Vice President Rare Diseases EMEA at Genzyme/Sanofi Genzyme. Hilde was also the General Manager at Pharmalink and Baxter Healthcare. She holds a Master of Science in Chemistry from the University of Oslo, Norway. She brings 35+ years of global leadership experience both as a Board member and through her years in global sales, marketing, strategy and management in the international Pharma/Biotech industries. She has management expertise in public and private companies of varying sizes. In addition to Herantis, her current Board assignments are: Bio-me (private, Norway), OncoZenge (listed, Sweden), PCI Biotech (listed, Norway), Tappin (private, Norway) and Calliditas (dual listed Sweden and Nasdaq, NY).

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson’s Disease, Alzheimer’s and other diseases. CDNF is a natural protein that occurs naturally in the body whose natural role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. CDNF – a biological protein – is Herantis’ lead program and a clinical stage asset; and xCDNF – a synthetic peptide version of CDNF – is Herantis’ follow-on program. Both CDNF and xCDNF have, via their multimodal mechanism of action, the potential improves neuronal survival and to stop the progression of Parkinson’s and other neurodegenerative disease and have a significant therapeutic impact on the lives of patients.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com